je.st
news
Home
› RedHill Biopharma - 9 Late Stage Clinical Assets, $150 Million Market Cap - Is It Undervalued?
RedHill Biopharma - 9 Late Stage Clinical Assets, $150 Million Market Cap - Is It Undervalued?
2015-09-11 14:41:16| Biotech - Topix.net
Every market day, we select up to 20 of our authors' top long and short ideas, exclusively for PRO subscribers. RedHill focuses on late stage oral gastrointestinal drugs; the company has two potential blockbusters in Phase 3 studies, 9 active clinical programs in total.
Tags: is
it
market
million
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||